We used our extensive network of contacts - key opinion leaders in the autophagy space - to test concepts and ideas
A start-up biotech company wanted to construct a business plan and allied presentations on how to develop and position inhibitors of a number of kinase targets that were known to modulate the intracellular process of autophagy.
The client challenge:
The client was aiming to develop new areas of biology that could be exploited therapeutically. A major challenge in constructing such a plan was the novelty of the area. They needed our help to perform an in-depth review of the literature and to create an appropriate drug discovery plan.
We used our extensive network of contacts - key opinion leaders in the autophagy space - to test concepts and ideas and from this were able to provide several groups who could provide assays, expertise and who were also keen to collaborate on future developments.
This included plans for chemical design, assay development, data interpretation and coordination to be conducted internally and all biology, medicinal chemistry and DMPK to be outsourced to top-quality specialist providers.
The Xenovium team was instrumental in negotiating contracts, providing a cost effective plan to run a high quality project with minimal internal FTE. Additionally, working together with the National Institute for Health Research (NIHR) in the UK, we investigated available resources to access translational medicine expertise through NOCRI (NIHR Office for Clinical Research Infrastructure) and constructed plans to run both preclinical models and to investigate potential biomarkers.
We used our literature review of autophagy, and the drug discovery plans to create a fully costed Business Plan. This was developed into a pitch presentation, which was delivered to Pharma, Biotech and VC audiences who praised the scientific credibility, technical feasibility and robustness of the proposal.
Chesterford Research Park, Little Chesterford, Saffron Walden, CB10 1XL